PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 24, 2026SHILAP Revista de lepidopterología0 citationsOpen Access

Case Report: Facial-limited eosinophilic annular erythema in a patient with rheumatoid arthritis: successful treatment with tofacitinib

MWMan-Ning WuYWYing WangYBYan-Ping Bai

Key Points

  • To highlight a rare facial variant of eosinophilic annular erythema in a rheumatoid arthritis patient and its treatment outcomes.
  • Case report of a 67-year-old male with facial lesions and rheumatoid arthritis.
  • Histopathological examination confirmed eosinophilic annular erythema without flame figures.
  • Treatment involved the use of tofacitinib, a Janus kinase inhibitor.
  • Facial plaques demonstrated dense dermal eosinophilia, consistent with eosinophilic annular erythema.
  • Tofacitinib treatment resulted in successful resolution of the skin lesions.
  • The lesion presentation was limited to the face, a rarity seen in approximately 3% of cases.

Abstract

We report a case of a 67-year-old man with rheumatoid arthritis (RA) presenting with symmetrical annular plaques confined to the face. Histopathology demonstrated dense dermal eosinophilia without flame figures, consistent with eosinophilic annular erythema (EAE). Unlike the typical truncal distribution, lesions were limited to the face, a presentation reported in approximately 3% of cases. The patient was successfully treated with tofacitinib, a Janus kinase (JAK) inhibitor. This report illustrates a rare facial variant of EAE and supports the efficacy of JAK inhibition in patients with concurrent RA.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Wu et al. (2026) studied this question.

synapsesocial.com/papers/69eb07a4553a5433e34b3304https://doi.org/10.3389/fimmu.2026.1792217
Ask AI
Helpful
Bookmark
Share
View Full Paper